ID VWF_CANLF Reviewed; 2813 AA. AC Q28295; Q28311; Q9TSI4; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2001, sequence version 2. DT 27-MAR-2024, entry version 157. DE RecName: Full=von Willebrand factor; DE Short=vWF; DE Flags: Precursor; GN Name=VWF; Synonyms=F8VWF; OS Canis lupus familiaris (Dog) (Canis familiaris). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Laurasiatheria; Carnivora; Caniformia; Canidae; Canis. OX NCBI_TaxID=9615; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Stoy S.J., Shibuya H., Nonneman D.J., Holzhauer J., Mohammed I.H., RA Johnson G.S.; RT "Canine vWF cDNA sequence."; RL Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], SUBUNIT, AND SUBCELLULAR LOCATION. RC TISSUE=Heart; RX PubMed=10961880; RA Haberichter S.L., Fahs S.A., Montgomery R.R.; RT "von Willebrand factor storage and multimerization: 2 independent RT intracellular processes."; RL Blood 96:1808-1815(2000). RN [3] RP SEQUENCE REVISION TO 55. RA Montgomery R.R., Fahs S., Montgomery M.W.; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA], AND DISEASE. RC STRAIN=Scottish terrier; TISSUE=Uterus; RX PubMed=10668811; DOI=10.1892/0891-6640(2000)014<0010:mcvwdi>2.3.co;2; RA Venta P.J., Li J., Yuzbasiyan-Gurkan V., Brewer G.J., Schall W.D.; RT "Mutation causing von Willebrand's disease in Scottish Terriers."; RL J. Vet. Intern. Med. 14:10-19(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1234-1669. RC TISSUE=Blood; RA Mancuso D.J., Christopherson P.A., Kroner P.A., Montgomery R.R.; RT "The canine von Willebrand factor gene: sequence and expression of a region RT encoding the glycoprotein Ib/IX binding domain."; RL Submitted (JAN-1994) to the EMBL/GenBank/DDBJ databases. RN [6] RP REVIEW. RX PubMed=12871266; DOI=10.1046/j.1538-7836.2003.00260.x; RA Ruggeri Z.M.; RT "von Willebrand factor, platelets and endothelial cell interactions."; RL J. Thromb. Haemost. 1:1335-1342(2003). CC -!- FUNCTION: Important in the maintenance of hemostasis, it promotes CC adhesion of platelets to the sites of vascular injury by forming a CC molecular bridge between sub-endothelial collagen matrix and platelet- CC surface receptor complex, glycoprotein Ibalpha/IX/V. Also acts as a CC chaperone for coagulation factor VIII, delivering it to the site of CC injury, stabilizing its heterodimeric structure and protecting it from CC premature clearance from plasma (By similarity). {ECO:0000250}. CC -!- SUBUNIT: Multimeric. Interacts with F8. {ECO:0000269|PubMed:10961880}. CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10961880}. Secreted, CC extracellular space, extracellular matrix CC {ECO:0000269|PubMed:10961880}. Note=Localized to storage granules. CC -!- TISSUE SPECIFICITY: Plasma. CC -!- DOMAIN: The propeptide is required for multimerization of vWF and for CC its targeting to storage granules. CC -!- PTM: All cysteine residues are involved in intrachain or interchain CC disulfide bonds. {ECO:0000250}. CC -!- PTM: N- and O-glycosylated. {ECO:0000250}. CC -!- DISEASE: Note=Defects in VWF are the cause of von Willebrand disease CC (VWD) in the Scottish Terrier. VWD is characterized by frequent CC bleeding. Type I VWD is associated with a deficiency of VWF; type II by CC normal to decreased plasma level of VWF; type III by a virtual absence CC of VWF. {ECO:0000269|PubMed:10668811}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L76227; AAB05549.1; -; mRNA. DR EMBL; U66246; AAB93766.2; -; mRNA. DR EMBL; AF099154; AAD04919.1; -; mRNA. DR EMBL; L16903; AAA30903.1; -; Genomic_DNA. DR RefSeq; NP_001002932.1; NM_001002932.1. DR SMR; Q28295; -. DR STRING; 9615.ENSCAFP00000053390; -. DR MEROPS; I08.950; -. DR MEROPS; I08.954; -. DR GlyCosmos; Q28295; 15 sites, No reported glycans. DR PaxDb; 9612-ENSCAFP00000022453; -. DR Ensembl; ENSCAFT00000083915.2; ENSCAFP00000065165.2; ENSCAFG00000015228.5. DR GeneID; 399544; -. DR KEGG; cfa:399544; -. DR CTD; 7450; -. DR VGNC; VGNC:48329; VWF. DR eggNOG; KOG1216; Eukaryota. DR InParanoid; Q28295; -. DR OrthoDB; 2872912at2759; -. DR Proteomes; UP000002254; Chromosome 27. DR Proteomes; UP000694429; Unplaced. DR Proteomes; UP000694542; Unplaced. DR Proteomes; UP000805418; Unplaced. DR GO; GO:0062023; C:collagen-containing extracellular matrix; ISS:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB. DR GO; GO:0031012; C:extracellular matrix; IBA:GO_Central. DR GO; GO:0005576; C:extracellular region; ISS:UniProtKB. DR GO; GO:0005615; C:extracellular space; IBA:GO_Central. DR GO; GO:0033093; C:Weibel-Palade body; ISS:UniProtKB. DR GO; GO:0005518; F:collagen binding; ISS:UniProtKB. DR GO; GO:0042802; F:identical protein binding; ISS:UniProtKB. DR GO; GO:0019865; F:immunoglobulin binding; ISS:UniProtKB. DR GO; GO:0005178; F:integrin binding; ISS:UniProtKB. DR GO; GO:0002020; F:protease binding; ISS:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; ISS:UniProtKB. DR GO; GO:0007596; P:blood coagulation; ISS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; ISS:UniProtKB. DR GO; GO:0031589; P:cell-substrate adhesion; ISS:UniProtKB. DR GO; GO:0007599; P:hemostasis; ISS:UniProtKB. DR GO; GO:0030168; P:platelet activation; ISS:UniProtKB. DR CDD; cd19941; TIL; 5. DR CDD; cd01450; vWFA_subfamily_ECM; 3. DR Gene3D; 2.10.25.10; Laminin; 5. DR Gene3D; 3.40.50.410; von Willebrand factor, type A domain; 3. DR InterPro; IPR006207; Cys_knot_C. DR InterPro; IPR036084; Ser_inhib-like_sf. DR InterPro; IPR002919; TIL_dom. DR InterPro; IPR037578; Von_Willebrand_factor. DR InterPro; IPR032361; VWA_N2. DR InterPro; IPR014853; VWF/SSPO/ZAN-like_Cys-rich_dom. DR InterPro; IPR002035; VWF_A. DR InterPro; IPR001007; VWF_dom. DR InterPro; IPR001846; VWF_type-D. DR InterPro; IPR036465; vWFA_dom_sf. DR PANTHER; PTHR11339; EXTRACELLULAR MATRIX GLYCOPROTEIN RELATED; 1. DR PANTHER; PTHR11339:SF361; VON WILLEBRAND FACTOR; 1. DR Pfam; PF08742; C8; 4. DR Pfam; PF01826; TIL; 4. DR Pfam; PF00092; VWA; 3. DR Pfam; PF16164; VWA_N2; 1. DR Pfam; PF00093; VWC; 2. DR Pfam; PF00094; VWD; 4. DR PIRSF; PIRSF002495; VWF; 1. DR PRINTS; PR00453; VWFADOMAIN. DR SMART; SM00832; C8; 4. DR SMART; SM00041; CT; 1. DR SMART; SM00327; VWA; 3. DR SMART; SM00214; VWC; 5. DR SMART; SM00215; VWC_out; 2. DR SMART; SM00216; VWD; 4. DR SUPFAM; SSF57603; FnI-like domain; 1. DR SUPFAM; SSF57567; Serine protease inhibitors; 5. DR SUPFAM; SSF53300; vWA-like; 3. DR PROSITE; PS01185; CTCK_1; 1. DR PROSITE; PS01225; CTCK_2; 1. DR PROSITE; PS50234; VWFA; 3. DR PROSITE; PS01208; VWFC_1; 3. DR PROSITE; PS50184; VWFC_2; 3. DR PROSITE; PS51233; VWFD; 4. PE 1: Evidence at protein level; KW Blood coagulation; Cell adhesion; Cleavage on pair of basic residues; KW Disulfide bond; Extracellular matrix; Glycoprotein; Hemostasis; KW Reference proteome; Repeat; Secreted; Signal. FT SIGNAL 1..22 FT /evidence="ECO:0000250" FT PROPEP 23..763 FT /evidence="ECO:0000250" FT /id="PRO_0000022680" FT CHAIN 764..2813 FT /note="von Willebrand factor" FT /id="PRO_0000022681" FT DOMAIN 33..201 FT /note="VWFD 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DOMAIN 295..348 FT /note="TIL 1" FT DOMAIN 386..560 FT /note="VWFD 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DOMAIN 652..707 FT /note="TIL 2" FT DOMAIN 776..827 FT /note="TIL 3" FT DOMAIN 865..1032 FT /note="VWFD 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DOMAIN 1146..1196 FT /note="TIL 4" FT DOMAIN 1277..1453 FT /note="VWFA 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00219" FT DOMAIN 1498..1665 FT /note="VWFA 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00219" FT DOMAIN 1691..1871 FT /note="VWFA 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00219" FT DOMAIN 1948..2124 FT /note="VWFD 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DOMAIN 2255..2328 FT /note="VWFC 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00220" FT DOMAIN 2429..2495 FT /note="VWFC 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00220" FT DOMAIN 2580..2645 FT /note="VWFC 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00220" FT DOMAIN 2724..2812 FT /note="CTCK" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00039" FT REGION 764..787 FT /note="Amino-terminal" FT REGION 788..833 FT /note="E1" FT REGION 826..853 FT /note="CX" FT REGION 2216..2261 FT /note="E2" FT MOTIF 531..533 FT /note="Cell attachment site" FT /evidence="ECO:0000255" FT MOTIF 698..700 FT /note="Cell attachment site" FT /evidence="ECO:0000255" FT MOTIF 2507..2509 FT /note="Cell attachment site" FT /evidence="ECO:0000255" FT CARBOHYD 99 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 156 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 211 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 666 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 857 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1231 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1515 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1574 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2223 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2290 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2357 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2400 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2546 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2585 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2790 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 35..162 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 57..200 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 388..524 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 410..559 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 432..440 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 767..808 FT /evidence="ECO:0000250" FT DISULFID 776..804 FT /evidence="ECO:0000250" FT DISULFID 810..821 FT /evidence="ECO:0000250" FT DISULFID 867..996 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 889..1031 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 898..993 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 914..921 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 1060..1084 FT /evidence="ECO:0000250" FT DISULFID 1071..1111 FT /evidence="ECO:0000250" FT DISULFID 1089..1091 FT /evidence="ECO:0000250" FT DISULFID 1126..1130 FT /evidence="ECO:0000250" FT DISULFID 1149..1169 FT /evidence="ECO:0000250" FT DISULFID 1153..1165 FT /evidence="ECO:0000250" FT DISULFID 1196..1199 FT /evidence="ECO:0000250" FT DISULFID 1234..1237 FT /evidence="ECO:0000250" FT DISULFID 1272..1458 FT /evidence="ECO:0000250" FT DISULFID 1669..1670 FT /evidence="ECO:0000250" FT DISULFID 1686..1872 FT /evidence="ECO:0000250" FT DISULFID 1879..1904 FT /evidence="ECO:0000250" FT DISULFID 1899..1940 FT /note="Or C-1899 with C-1942" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00039, FT ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 1927..2088 FT /evidence="ECO:0000250" FT DISULFID 1950..2085 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 1972..2123 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 1993..2001 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00580" FT DISULFID 2724..2774 FT /evidence="ECO:0000250" FT DISULFID 2739..2788 FT /evidence="ECO:0000250" FT DISULFID 2750..2804 FT /evidence="ECO:0000250" FT DISULFID 2754..2806 FT /evidence="ECO:0000250" FT DISULFID ?..2811 FT /evidence="ECO:0000250" FT CONFLICT 70 FT /note="V -> I (in Ref. 4; AAD04919)" FT /evidence="ECO:0000305" FT CONFLICT 266 FT /note="A -> G (in Ref. 2; AAB93766)" FT /evidence="ECO:0000305" FT CONFLICT 280 FT /note="I -> V (in Ref. 2; AAB93766)" FT /evidence="ECO:0000305" FT CONFLICT 409..411 FT /note="VCH -> ICQ (in Ref. 2; AAB93766)" FT /evidence="ECO:0000305" FT CONFLICT 994 FT /note="G -> A (in Ref. 1; AAB05549)" FT /evidence="ECO:0000305" FT CONFLICT 1021 FT /note="F -> L (in Ref. 2; AAB93766)" FT /evidence="ECO:0000305" FT CONFLICT 2381 FT /note="L -> P (in Ref. 2; AAB93766)" FT /evidence="ECO:0000305" FT CONFLICT 2406 FT /note="P -> L (in Ref. 2; AAB93766)" FT /evidence="ECO:0000305" SQ SEQUENCE 2813 AA; 309719 MW; 5DF93E1E5E72F80C CRC64; MSPTRLVRVL LALALILPGK LCTKGTVGRS SMARCSLFGG DFINTFDESM YSFAGDCSYL LAGDCQEHSV SLIGGFQNGK RVSLSVYLGE FFDIHLFVNG TMLQGTQSIS MPYASNGLYL EAEAGYYKLS SEAYGFVARI DGNGNFQVLL SDRYFNKTCG LCGNFNIFAE DDFRTQEGTL TSDPYDFANS WALSSGEQRC KRVSPPSSPC NVSSDEVQQV LWEQCQLLKS ASVFARCHPL VDPEPFVALC ERTLCTCVQG MECPCAVLLE YARACAQQGI VLYGWTDHSV CRPACPAGME YKECVSPCTR TCQSLHVKEV CQEQCVDGCS CPEGQLLDEG HCVGSAECSC VHAGQRYPPG ASLLQDCHTC ICRNSLWICS NEECPGECLV TGQSHFKSFD NRYFTFSGVC HYLLAQDCQD HTFSVVIETV QCADDLDAVC TRSVTVRLPG HHNSLVKLKH GGGVSMDGQD IQIPLLQGDL RIQHTVMASV RLSYGEDLQM DWDGRGRLLV TLSPAYAGKT CGLCGNYNGN RGDDFVTPAG LAEPLVEDFG NAWKLLGACE NLQKQHRDPC SLNPRQARFA EEACALLTSS KFEPCHRAVG PQPYVQNCRY DVCSCSDGRD CLCSAVANYA AACARRGVHI AWREPGFCAL SCPQGQVYLQ CGTPCNMTCR SLSYPEEDCN EVCLEGCFCP PGLYLDERGD CVPKAQCPCY YDGEIFQPED IFSDHHTMCY CEDGFMHCTT SGGLGSLLPN PVLSSPRSHR SKRSLSCRPP MVKLVCPADN PRAEGLECAK TCQNYDLQCM STGCVSGCLC PQGMVRHENR CVALERCPCF HQGQEYAPGE TVKIDCNTCV CRDRKWNCTD HVCDATCSAI GMAHYLTFDG LKYLFPGECQ YVLVQDYCGS NPGTFRILVG NEGCSYPSVK CKKRVTILVE GGEIELFDGE VNVKKPMKDE THFEVVESGQ YVILLLGKAL SVVWDHRLSI SVTLKRTYQE QVCGLCGNFD GIQNNDFTSS SLQIEEDPVD FGNSWKVNPQ CADTKKVPLD SSPAVCHNNI MKQTMVDSSC RILTSDIFQD CNRLVDPEPF LDICIYDTCS CESIGDCTCF CDTIAAYAHV CAQHGKVVAW RTATFCPQNC EERNLHENGY ECEWRYNSCA PACPITCQHP EPLACPVQCV EGCHAHCPPG KILDELLQTC IDPEDCPVCE VAGRRLAPGK KIILNPSDPE HCQICHCDGV NFTCQACREP GSLVVPPTEG PIGSTTSYVE DTPEPPLHDF HCSRLLDLVF LLDGSSKLSE DEFEVLKVFV VGMMEHLHIS QKRIRVAVVE YHDGSHAYIE LKDRKRPSEL RRITSQVKYA GSEVASTSEV LKYTLFQIFG KIDRPEASRI ALLLMASQEP SRLARNLVRY VQGLKKKKVI VIPVGIGPHA SLKQIHLIEK QAPENKAFVF SGVDELEQRR DEIINYLCDL APEAPAPTQH PPMAQVTVGS ELLGVSSPGP KRNSMVLDVV FVLEGSDKIG EANFNKSREF MEEVIQRMDV GQDRIHVTVL QYSYMVTVEY TFSEAQSKGE VLQQVRDIRY RGGNRTNTGL ALQYLSEHSF SVSQGDREQV PNLVYMVTGN PASDEIKRMP GDIQVVPIGV GPHANVQELE KIGWPNAPIL IHDFEMLPRE APDLVLQRCC SGEGLQIPTL SPTPDCSQPL DVVLLLDGSS SIPASYFDEM KSFTKAFISR ANIGPRLTQV SVLQYGSITT IDVPWNVAYE KVHLLSLVDL MQQEGGPSQI GDALSFAVRY VTSEVHGARP GASKAVVILV TDVSVDSVDA AAEAARSNRV TVFPIGIGDR YSEAQLSSLA GPKAGSNMVR LQRIEDLPTV ATLGNSFFHK LCSGFDRVCV DEDGNEKRPG DVWTLPDQCH TVTCLPDGQT LLKSHRVNCD RGPRPSCPNG QPPLRVEETC GCRWTCPCVC MGSSTRHIVT FDGQNFKLTG SCSYVLFQNK EQDLEVILHN GACSPGAKET CMKSIEVKHD GLSVELHSDM QMTVNGRLVS IPYVGGDMEV NVYGTIMYEV RFNHLGHIFT FTPQNNEFQL QLSPRTFASK TYGLCGICDE NGANDFILRD GTVTTDWKAL IQEWTVQQLG KTCQPVPEEQ CPVSSSSHCQ VLLSELFAEC HKVLAPATFY AMCQPDSCHP KKVCEAIALY AHLCRTKGVC VDWRRANFCA MSCPPSLVYN HCEHGCPRLC EGNTSSCGDQ PSEGCFCPPN QVMLEGSCVP EEACTQCISE DGVRHQFLET WVPAHQPCQI CTCLSGRKVN CTLQPCPTAR APTCGPCEVA RLRQNAEQCC PEYECVCDLV SCDLPPVPPC EDGLQMTLTN PGECRPNFTC ACRKDECRRE SPPSCPPHRT LALRKTQCCD EYECACNCVN STVSCPLGYL ASAVTNDCGC TTTTCFPDKV CVHRGTIYPV GQFWEEACDV CTCTDLEDSV MGLRVAQCSQ KPCEDNCLSG FTYVLHEGEC CGRCLPSACE VVIGSPRGDA QSHWKNVGSH WASPDNPCLI NECVRVKEEV FVQQRNVSCP QLNVPTCPTG FQLSCKTSEC CPTCHCEPLE ACLLNGTIIG PGKSLMIDVC TTCRCTVQVG VISGFKLECR KTTCEACPLG YKEEKNQGEC CGRCLPIACT IQLRGGQIMT LKRDETIQDG CDSHFCKVNE RGEYIWEKRV TGCPPFDEHK CLAEGGKIMK IPGTCCDTCE EPECKDIIAK LQRVKVGDCK SEEEVDIHYC EGKCASKAVY SIHMEDVQDQ CSCCSPTQTE PMQVPLRCTN GSLIYHEILN AMQCRCSPRK CSK //